New combo aims to tackle lung cancer after immunotherapy fails

NCT ID NCT06903377

Recruiting now Disease control Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new combination of two drugs—ZG005 (given by IV) and gecacitinib (taken as a pill)—in 50 adults with advanced non-small cell lung cancer that has not responded to prior PD-1/L1 therapy. The goal is to see if the combination is safe and can shrink tumors. Participants must be 18-75 and cannot have brain metastases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZG005 (a biologic) combined with gecacitinib (a pill)
What this could lead to: If it works, this could offer a new treatment option for people with advanced lung cancer that has stopped responding to standard immunotherapy.
What could go wrong: This is an early-phase trial with only 50 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai Chest Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.